Alterity issues 43.5M employee incentive options

Alterity Therapeutics Limited has reported the grant of 43,500,000 unlisted options under its employee incentive scheme.

Rhea-AI Filing Summary

Alterity Therapeutics Limited has reported the grant of 43,500,000 unlisted options under its employee incentive scheme. These options have an exercise price of USD 0.0057 and expire on 13 January 2031, and are in a new unquoted class that will convert into ordinary fully paid ATH shares if exercised. None of the options were issued to key management personnel, and the issue was made under exception 13 in ASX Listing Rule 7.2, meaning separate security holder approval was not required. Following this grant, Alterity continues to have over 10.8 billion ordinary shares quoted on ASX along with several other series of quoted and unquoted options on issue.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alterity Therapeutics (ATHE) announce in this Form 6-K?

Alterity Therapeutics Limited announced the issue of 43,500,000 unlisted options under an employee incentive scheme. These options form a new, unquoted class on ASX and are intended as employee incentives rather than listed securities.

How many new options did Alterity Therapeutics issue and on what terms?

The company issued 43,500,000 unlisted options with an exercise price of USD 0.0057 per option and an expiry date of 13 January 2031. All options in this new class rank equally from their issue date of 15 January 2026.

What will holders receive when they exercise these new Alterity options?

On exercise, each new option will result in the issue of an ATH ordinary fully paid share. The options are denominated in US dollars and are not intended to be quoted on ASX.

Were any of the new employee incentive options issued to key management personnel at Alterity Therapeutics?

No. The filing states that none of the options were issued to key management personnel or their associates, indicating they were granted to other eligible participants in the employee incentive scheme.

Did Alterity Therapeutics need shareholder approval for this option issue?

The company indicates the options were issued under exception 13 in ASX Listing Rule 7.2, so the issue did not require separate security holder approval under Listing Rule 7.1.

What other quoted securities does Alterity Therapeutics have on issue after this grant?

After this grant, the company has 10,875,416,329 ATH ordinary fully paid shares quoted on ASX, along with quoted options including ATHO options expiring 31 August 2026 and ATHOA options expiring 26 February 2027, in addition to several unquoted option series.

How many unquoted option series, including the new class, does Alterity have outstanding?

The filing lists multiple unquoted option classes such as ATHAAE, ATHAAG, ATHAE, ATHAF, ATHAD, ATHAAK, ATHAAH, ATHAB, ATHAA, ATHAC, plus the new unlisted options expiring 13 January 2031 totaling 43,500,000 options in that new class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 06:28 AM EST Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 15, 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Notification regarding unquoted securities - ATH

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: January 15, 2026

2

Exhibit 99.1

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Announcement Summary

Entity name

ALTERITY THERAPEUTICS LIMITED

Date of this announcement

Thursday January 15, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code		Security description		Total number of + securities to be issued/transferred		Issue date
New class - code to be confirmed		Unlisted options expiring 13 January 2031, ex US$0.0057		43,500,000		15/01/2026

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 1 - Entity and announcement details

1.1 Name of entity

ALTERITY THERAPEUTICS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

	1.2 Registered number type		Registration number
	ABN		37080699065

1.3 ASX issuer code

ATH

1.4 The announcement is

New announcement

1.5 Date of this announcement

15/1/2026

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code (“new class”)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 3C - number and type of +securities the subject of this notification (new class)

	ASX +security code		+Security description
	New class - code to be confirmed		Unlisted options expiring 13 January 2031, ex US$0.0057

	+Security type		ISIN code
	Options

Date the +securities the subject of this notification were issued

15/1/2026

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Options Details

	+Security currency		Exercise price		Expiry date
	USD - US Dollar		USD 0.00570000		13/1/2031

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

ATH : ORDINARY FULLY PAID

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

https://app.sharelinktechnologies.com/announcement-preview/asx/0e52c57244a1691e13a67c0caf2d50fb

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

43,500,000

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

		Total number of
ASX +security code and description		+securities on issue
ATH : ORDINARY FULLY PAID			10,875,416,329
ATHO : OPTION EXPIRING 31-AUG-2026			931,232,089
ATHOA : OPTION EXPIRING 26-FEB-2027			1,222,300,911

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) 

		Total number of
ASX +security code and description		+securities on issue
ATHAAE : OPTION EXPIRING 29-NOV-2026 EX $0.0375			10,000,000
ATHAAG : OPTION EXPIRING 29-NOV-2026 EX $0.0238			11,500,000
ATHAE : OPTION EXPIRING 08-AUG-2030 EX $0.013			11,500,000
ATHAF : OPTION EXPIRING 08-AUG-2030 EX USD 0.0086			312,400,200
ATHAD : OPTION EXPIRING 01-JUL-2030 EX $0.01			15,000,000
ATHAAK : OPTION EXPIRING 30-DEC-2027 EX $0.01			170,000,000
ATHAAH : OPTION EXPIRING 19-DEC-2026 EX $0.0105			8,000,000
ATHAB : OPTION EXPIRING 13-MAR-2029 EX US$0.0031			62,500,000
ATHAA : OPTION EXPIRING 13-MAR-2029 EX $0.004			20,166,667
ATHAC : OPTION EXPIRING 21-MAR-2029 EX US$0.003			40,000,200
New class - code to be confirmed : Unlisted options expiring 13 January 2031 ex US$0.0057			43,500,000

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6